<!DOCTYPE html>
<html lang="en">
<head>
  
  
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    
    
    <link rel="canonical" href="https://jzpero.github.io/mednotes/Hematology/Thrombosis/Pulmonary%20Embolism/">
    <link rel="shortcut icon" href="../../../img/favicon.ico">
    <meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=1.0, user-scalable=0" />
    <title>Pulmonary Embolism - MedNotes</title>
    <link href="../../../css/bootstrap-3.3.7.min.css" rel="stylesheet">
    <link href="../../../css/font-awesome-4.7.0.css" rel="stylesheet">
    <link href="../../../css/base.css" rel="stylesheet">
    <link rel="stylesheet" href="../../../css/highlight.css">
    <!-- HTML5 shim and Respond.js IE8 support of HTML5 elements and media queries -->
    <!--[if lt IE 9]>
        <script src="https://oss.maxcdn.com/libs/html5shiv/3.7.0/html5shiv.js"></script>
        <script src="https://oss.maxcdn.com/libs/respond.js/1.3.0/respond.min.js"></script>
    <![endif]-->

    <script src="../../../js/jquery-3.2.1.min.js"></script>
    <script src="../../../js/bootstrap-3.3.7.min.js"></script>
    <script src="../../../js/highlight.pack.js"></script>
    
    <base target="_top">
    <script>
      var base_url = '../../..';
      var is_top_frame = false;
        
        var pageToc = [
          {title: "Pulmonary Embolism", url: "#_top", children: [
          ]},
          {title: "Evaluation", url: "#evaluation", children: [
              {title: "Risk Stratification", url: "#risk-stratification" },
              {title: "RV Assessment", url: "#rv-assessment" },
          ]},
          {title: "Resuscitation of PE", url: "#resuscitation-of-pe", children: [
          ]},
          {title: "Treatment Strategy", url: "#treatment-strategy", children: [
              {title: "Massive PE", url: "#massive-pe" },
              {title: "Submassive/Intermediate Risk PE", url: "#submassiveintermediate-risk-pe" },
              {title: "Low-Risk PE", url: "#low-risk-pe" },
              {title: "Subsegmental PE", url: "#subsegmental-pe" },
          ]},
          {title: "Thrombolysis", url: "#thrombolysis", children: [
              {title: "Massive PE", url: "#massive-pe_1" },
              {title: "Intermediate Risk PE", url: "#intermediate-risk-pe" },
              {title: "Cardiac Arrest", url: "#cardiac-arrest" },
          ]},
          {title: "Anticoagulation", url: "#anticoagulation", children: [
          ]},
          {title: "Special Populations", url: "#special-populations", children: [
          ]},
          {title: "References", url: "#references", children: [
          ]},
        ];

    </script>
    <script src="../../../js/base.js"></script> 
</head>

<body>
<script>
if (is_top_frame) { $('body').addClass('wm-top-page'); }
</script>



<div class="container-fluid wm-page-content">
  <a name="_top"></a>
    

    
    
      
    

  <div class="row wm-article-nav-buttons" role="navigation" aria-label="navigation">
    
    <div class="wm-article-nav pull-right">
      <a href="../Warfarin/" class="btn btn-xs btn-default pull-right">
        Next
        <i class="fa fa-chevron-right" aria-hidden="true"></i>
      </a>
      <a href="../Warfarin/" class="btn btn-xs btn-link">
        Acetaminophen interacts with Vitamin K antagonism
      </a>
    </div>
    
    <div class="wm-article-nav">
      <a href="../Cancer%20Associated%20Thrombosis/" class="btn btn-xs btn-default pull-left">
        <i class="fa fa-chevron-left" aria-hidden="true"></i>
        Previous</a><a href="../Cancer%20Associated%20Thrombosis/" class="btn btn-xs btn-link">
        Cancer-Associated Thrombosis
      </a>
    </div>
    
  </div>

    

    <h1 id="pulmonary-embolism">Pulmonary Embolism</h1>
<h1 id="evaluation">Evaluation</h1>
<h2 id="risk-stratification">Risk Stratification</h2>
<p>Per the ESC 2019 Guidelines, patients are separated into <strong>High, Intermediate-High, Intermediate-Low, or Low risk</strong> for early mortality.</p>
<p><img alt="" src="../_attachments/ehz405ilf3.jpeg" /></p>
<h3 id="high-risk-or-massive-pe">High-Risk, or Massive PE</h3>
<ul>
<li>These patients present with hemodynamic instability, evidence of RV dysfunction, and possibly elevated cardiac enzymes.</li>
<li>Hemodynamic instability is defined as:<ol>
<li>Hypotension (SBP &lt; 90 mmHg for 15 minutes, fall in SBP &gt;40 mmHg from baseline for 15 minutes), vasopressor requirement, or cardiac arrest</li>
<li>Exclusion of sepsis, hypovolemic, new arrhythmia</li>
</ol>
</li>
</ul>
<h3 id="intermediate-risk-or-submassive-pe">Intermediate Risk, or Submassive PE</h3>
<ul>
<li>These patients have evidence of RV dysfunction, may have elevated cardiac enzymes, or an elevated PESI risk (class III-IV or sPESI &gt;= 1)</li>
</ul>
<h3 id="low-risk">Low-Risk</h3>
<ul>
<li>No hemodynamic compromise, normal cardiac enzymes (if tested), and no evidence of RV dysfunction</li>
<li>low PESI risk class (I or II), sPESI = 0</li>
</ul>
<h2 id="rv-assessment">RV Assessment</h2>
<p>Either with echocardiography or CT angiography.</p>
<h1 id="resuscitation-of-pe">Resuscitation of PE</h1>
<ol>
<li>Volume management</li>
<li>Early vasopressors (NE) +/- inotropes (dobutamine)</li>
<li>Consider thrombolysis</li>
<li>Avoid <a href="../../../Critical%20Care/Procedures/Intubation/">intubation</a></li>
<li>Consider ECMO for refractory cases</li>
</ol>
<h1 id="treatment-strategy">Treatment Strategy</h1>
<h2 id="massive-pe">Massive PE</h2>
<ul>
<li>Strongly consider <strong>thrombolysis with tPA</strong> (make sure to review absolute and relative contraindications to thrombolysis).</li>
<li>If there are absolute contraindications to lytics, then consider <strong>IR clot removal or surgical embolectomy</strong>.</li>
</ul>
<h2 id="submassiveintermediate-risk-pe">Submassive/Intermediate Risk PE</h2>
<h3 id="intermediate-high">Intermediate-High</h3>
<ul>
<li>If there are no absolute contraindications to lysis, then consider smaller dose of tPA (0.5 mg/kg up to maximum 50 mg) over 2 hours</li>
<li>If there are relative contraindications consider 25 mg tPA as a slow infusion</li>
<li>If there are absolute contraindications then anticoagulation alone is preferred.</li>
</ul>
<h3 id="intermediate-low">Intermediate-Low</h3>
<p>Anticoagulation alone.</p>
<h2 id="low-risk-pe">Low-Risk PE</h2>
<p>Anticoagulation alone.</p>
<h2 id="subsegmental-pe">Subsegmental PE</h2>
<ul>
<li>Contentious area. A 2021 <a href="https://www.acpjournals.org/doi/10.7326/M21-2981">study</a> found that the risk of 90-day recurrent VTE in non-anticoagulated patients with isolated single SSPE was ~2%, and those with multiple is about ~5.7%. Interesting, the 90-day risk of recurrent VTE in patients treated with anticoagulation is approx 3% based on prior studies. Therefore, there might not be a clinically significant risk reduction with full anticoagulation for patients with a single SSPE.</li>
<li>The 2021 CHEST guidelines recommend <strong>surveillence</strong> over anticoagulation for those with low risk of recurrent VTE, and <strong>anticoagulation</strong> over surveillance for those at high risk of recurrent VTE. This only applies if proximal DVT is ruled out (with ultrasonography)</li>
</ul>
<div class="admonition note">
<p class="admonition-title">What is the takeaway?</p>
<p>As of 2022, if the patient has a single SSPE and no particular risk factors for recurrence or decompensation (active cancer, cardiopulmonary poor dysfunction, completely unprovoked), and bilateral compression US is negative for DVT, then <em>it is reasonable to consider no anticoagulation</em> and close monitoring instead (with perhaps repeat ultrasounds in 2-3 weeks).</p>
</div>
<h1 id="thrombolysis">Thrombolysis</h1>
<ul>
<li>Hold anticoagulation (IV heparin) before and during the infusion. Fully anticoagulate patients with IV UFH afterwards (resume without bolus when aPTT &lt;2x ULN). Then, transition to oral agent once stable for 24-48 hours.</li>
<li>a consistent finding among studies is that thrombolytic therapy leads to early hemodynamic improvement and, although a mortality benefit may exist, it occurs at a cost of increased major bleeding. Per the ESC 2019 guidelines: Thrombolytic therapy leads to faster improvements in pulmonary obstruction, PAP, and PVR in patients with PE, compared with UFH alone; these improvements are accompanied by a reduction in RV dilation on echocardiography.</li>
<li>10% risk of severe bleeding, 1.7% risk of <a href="../../../Critical%20Care/Neuro%20Critical%20Care/Intracranial%20Hemorrhage/">intracranial hemorrhage</a> (SRMA)</li>
</ul>
<h2 id="massive-pe_1">Massive PE</h2>
<ul>
<li>FDA approved regimen: IV tPA (alteplase) 100 mg over 2 hours.</li>
<li>Consider in more urgent situations (none are shown to be superior)<ul>
<li>infusion over 15 minutes</li>
<li>20 mg IV bolus then 80 mg IV over 2 hours</li>
</ul>
</li>
</ul>
<h2 id="intermediate-risk-pe">Intermediate Risk PE</h2>
<p>While not routinely considered, thrombolysis can be considered for patients on anticoagulation who are decompensating or have higher risk of early mortality, anticoagulation treatment.</p>
<p>Some studies (particularly <strong>PEITHO</strong>) have examined thrombolysis in submassive PE and generally find no balanced benefit from thrombolysis (perhaps improved hemodynamic or <a href="../../../Respirology/Pulmonary%20Hypertension/">pulmonary hypertension</a> status, against increased bleeding risk). The <strong>MOPETT</strong> study used a particular regimen of tPA 0.5 mg/kg (up to a max of 50 mg) given as a 10 mg bolus followed by the remainder over 2 hours (i.e. reduced dose) for a particular definition of submassive PE ("moderate", with few patients having RV dysfunction); it showed that the risk of <a href="../../../Respirology/Pulmonary%20Hypertension/">pulmonary hypertension</a> was reduced compared to anticoagulation alone.</p>
<div class="admonition info">
<p class="admonition-title">PEITHO (NEJM 2014)</p>
<p>Among patients with submassive PE being treated with unfractionated heparin, administration of tenecteplase (30-50 mg IV once over 5-10 seconds) reduces a composite endpoint of all-cause mortality or hemodynamic decompensation at 7 days when compared to placebo, though this was driven by reduced hemodynamic decompensation. Tenecteplase was associated with increased rates of major extracranial bleeding at 7 days (6.3% vs. 1.2%; P&lt;0.001; NNH 20) and strokes at 7 days (2.4% vs. 0.2%; P=0.004; NNH 45).</p>
</div>
<h2 id="cardiac-arrest">Cardiac Arrest</h2>
<ul>
<li>Give a 50 mg IV tPA <em>bolus</em> over 2 minutes, consider also starting a vasopressor early  if in PEA arrest (obtain aterial access, use POCUS ECHO!). Follow with another 50 mg IV bolus after 15 minutes in the absence of ROSC.</li>
<li>once a thrombolytic drug is administered, cardiopulmonary resuscitation should be continued for at least 60â€“90 min before terminating resuscitation attempts (ESC 2019)</li>
</ul>
<h1 id="anticoagulation">Anticoagulation</h1>
<ul>
<li>Massive/high risk PE --&gt; IV UFH with bolus dose</li>
<li>Intermediate or low-risk PE --&gt; LMWH or fondaparinux or OAC (DOAC or VKA with bridging)</li>
</ul>
<h1 id="special-populations">Special Populations</h1>
<ul>
<li>Malignancy: <a href="../Cancer%20Associated%20Thrombosis/">Cancer Associated Thrombosis</a></li>
<li>Pregnancy:</li>
<li>Renal failure: IV UFH, VKA</li>
<li>Prohibitive bleeding risk which is a contraindication to anticoagulation (active bleeding, surgery, etc).<ul>
<li>Further exclude DVT</li>
<li>Consider IVC filter</li>
</ul>
</li>
</ul>
<h1 id="references">References</h1>
<ol>
<li><a href="https://academic.oup.com/eurheartj/article/41/4/543/5556136">2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS) | European Heart Journal | Oxford Academic</a></li>
<li><a href="https://emcrit.org/ibcc/pe/#is_PE_driving_the_patient's_instability?">Submassive &amp; Massive PE - EMCrit Project</a></li>
<li><a href="https://www.uptodate.com/contents/treatment-prognosis-and-follow-up-of-acute-pulmonary-embolism-in-adults#H4">UptoDate</a></li>
<li><a href="https://emcrit.org/pulmcrit/eight-pearls-for-the-crashing-patient-with-massive-pe/">Eight pearls for the crashing patient with massive PE</a></li>
</ol>

  <br>
    

    
    
      
    

  <div class="row wm-article-nav-buttons" role="navigation" aria-label="navigation">
    
    <div class="wm-article-nav pull-right">
      <a href="../Warfarin/" class="btn btn-xs btn-default pull-right">
        Next
        <i class="fa fa-chevron-right" aria-hidden="true"></i>
      </a>
      <a href="../Warfarin/" class="btn btn-xs btn-link">
        Acetaminophen interacts with Vitamin K antagonism
      </a>
    </div>
    
    <div class="wm-article-nav">
      <a href="../Cancer%20Associated%20Thrombosis/" class="btn btn-xs btn-default pull-left">
        <i class="fa fa-chevron-left" aria-hidden="true"></i>
        Previous</a><a href="../Cancer%20Associated%20Thrombosis/" class="btn btn-xs btn-link">
        Cancer-Associated Thrombosis
      </a>
    </div>
    
  </div>

    <br>
</div>

<footer class="container-fluid wm-page-content">
  <p>Documentation built with <a href="https://www.mkdocs.org/">MkDocs</a> using <a href="https://github.com/gristlabs/mkdocs-windmill">Windmill</a> theme by Grist Labs.</p>
</footer>

</body>
</html>